Cart
sales@molnova.com
GSK-2324
CAS No. 1020567-30-9
GSK-2324( GSK2324 | GSK 2324 )
Catalog No. M10099 CAS No. 1020567-30-9
GSK-2324 (GSK2324) is a potent, selective, full FXR agonist with EC50 of 120 nM in FRET assay.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 787 | In Stock |
|
| 10MG | 1074 | In Stock |
|
| 25MG | 1596 | In Stock |
|
| 50MG | 2130 | In Stock |
|
| 100MG | 2762 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK-2324
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK-2324 (GSK2324) is a potent, selective, full FXR agonist with EC50 of 120 nM in FRET assay.
-
DescriptionGSK-2324 (GSK2324) is a potent, selective, full FXR agonist with EC50 of 120 nM in FRET assay; lowers body weight gain and serum glucose in a DIO mouse model of diabetes.
-
In Vitro——
-
In Vivo——
-
SynonymsGSK2324 | GSK 2324
-
PathwayMetabolic Enzyme/Protease
-
TargetFXR
-
RecptorFXR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1020567-30-9
-
Formula Weight533.405
-
Molecular FormulaC29H22Cl2N2O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC(C)C1=C(C(=NO1)C2=C(C=CC=C2Cl)Cl)COC3=CC=C(C=C3)C4=CC5=C(C=C4)N=C(C=C5)C(=O)O
-
Chemical Name6-(4-((3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl)methoxy)phenyl)quinoline-2-carboxylic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Bass JY, et al. Bioorg Med Chem Lett. 2011 Feb 15;21(4):1206-13.
2. de Aguiar Vallim TQ, et al. Circ Res. 2013 Jun 7;112(12):1602-12.
molnova catalog
related products
-
WAY-362450
A highly potent, selective, and orally active agonist of FXR with EC50 of 4 nM.
-
Lithocholic acid
Lithocholic acid is a toxic secondary bile acid, causes intrahepatic cholestasis, has tumor-promoting activity.
-
Chenodeoxycholic Aci...
Chenodeoxycholic Acid sodium salt (CDCA sodium salt) is a bile acid in humans that activates the nuclear receptor FXR, rescues axonal degeneration of induced pluripotent stem cell-derived neurons in patients with spastic paraplegia type 5 and cerebral xanthomatosis, and can be used to study pancreatic necrosis.
